GlassScriptPhysician profile
Stephanie Carter
NPI 1699134023
$2,092.25
in general payments reported to CMS, 2019-2025
24 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $564 · 2023: $479 · 2024: $446 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.02 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $319.83 | 2023-2024 | Gemtesa, Orgovyx |
| Urovant Sciences INC | $309.93 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $286.55 | 2021-2024 | Xiaflex |
| Astellas Pharma US INC | $211.44 | 2021-2025 | Myrbetriq |
| Procept Biorobotics Corporation | $154.02 | 2024-2025 | Aquabeam System |
| Clarus Therapeutics INC. | $149.51 | 2021 | |
| Pfizer INC. | $117.43 | 2023-2025 | |
| Axonics, INC. | $57.00 | 2023 | Axonics |
| Urogen Pharma, INC. | $52.07 | 2023-2024 | Jelmyto |
| 180 Medical, INC. | $51.01 | 2021-2024 | Gentlecath Glide |
| Abbvie INC. | $50.51 | 2023-2025 | |
| Olympus America INC. | $50.14 | 2022-2025 | Olympus, Itind System |
| Endo USA, INC. | $44.29 | 2024 | Xiaflex |
| Dendreon Pharmaceuticals LLC | $42.06 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $32.70 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29.12 | 2021-2025 | Rezum Generator |
| Medtronic, INC. | $26.23 | 2021 | |
| Myriad Genetic Laboratories, INC. | $23.63 | 2024 | Prolaris |
| Tolmar, INC. | $22.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.70 | 2021 | |
| Calyxo, INC. | $15.45 | 2024 | Cvac Aspiration System |
| Profound Medical Corp. | $14.41 | 2022 | |
| Myovant Sciences INC. | $14.28 | 2021 | |
| Travere Therapeutics, INC. | $2.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.